ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer's disease trial.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04468659 (AHEAD 3-45 Study), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm, 216 Week Study With an Extension Phase to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer's Disease and Elevated Amyloid (A45 Trial) and in Subjects With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (A3 Trial)
Who cites it
29 citing papers in PubMed, 34 citations in OpenAlex.
- Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.Annals of neurology · 2026Trial
- Late-life body mass index and amyloid interaction on cognitive decline in unimpaired older adults.The journal of prevention of Alzheimer's disease · 2026Trial
- Recruitment and retention in a preclinical AD trial: comparisons between academic and non-academic sites.Alzheimer's research & therapy · 2025Trial
- Financial Incentives to Increase Diversity of Older Participants in a Memory Concerns Registry: A Randomized Clinical Trial.JAMA health forum · 2025Trial
- Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies.The journal of prevention of Alzheimer's disease · 2024Trial
- Perspectives from Alzheimer's Disease Research Centers site directors on the early steps and the lasting impact.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Differences in amyloid PET positivity based on ethnoracial group and social determinants of health: The new IDEAS study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Racial and Ethnic Representation in Dementia Clinical Trials Registered on ClinicalTrials.gov in the United States, United Kingdom, and Canada.International journal of geriatric psychiatry · 2026Article
- Evolving Alzheimer's Disease Clinical Practice: Updated Diagnostic Criteria, Fluid Biomarkers, and Special Considerations for Anti-Amyloid Therapies.Psychiatry investigation · 2026Article
- The roles of biomarkers in Alzheimer's disease clinical trials.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Solving the 'Goldilocks problem' in dementia clinical trials with multimodal AI.The journal of prevention of Alzheimer's disease · 2025Article
- Sphingolipid and ceramide associations with tau pathology vary across diverse ethnoracial groups in postmortem brain tissue.medRxiv : the preprint server for health sciences · 2025Article
- Characterizing the Research Participant Recruitment Funnel for Alzheimer's Secondary Prevention Trials: Results from A National Survey of U.S. Adults.Alzheimer's & dementia. Behavior & socioeconomics of aging · 2025Article
- Advancing the science of recruitment for Alzheimer's clinical trials: Challenges and opportunities.The journal of prevention of Alzheimer's disease · 2025Review
- Comparison of plasma p-tau217/Aβ42, p-tau217, and Aβ42/Aβ40 biomarkers by race to detect Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Alzheimer's Disease: Treatment Challenges for the Future.Journal of neurochemistry · 2025Review
- Evaluation of plasma p-tau217 for detecting amyloid pathology in a heterogeneous community-based cohort.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Novel set of plasma proteins classifies Alzheimer's dementia in African American individuals with high accuracy.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Impact of racialization on neuroimaging and plasma biomarkers of Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Global Diseases Deserve Global Solutions: Alzheimer's Disease.Neurology international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 8 institutions in 1 country.
Funding
Abstract
introductionIn trials of amyloid-lowering drugs for Alzheimer's disease (AD), differential eligibility may contribute to under-inclusion of racial and ethnic underrepresented groups. We examined plasma amyloid beta 42/40 and positron emission tomography (PET) amyloid eligibility for the ongoing AHEAD Study preclinical AD program (NCT04468659).
methodsUnivariate logistic regression models were used to examine group differences in plasma and PET amyloid screening eligibility.
resultsOf 4905 participants screened at time of analysis, 1724 were plasma eligible to continue in screening: 13.3% Hispanic Black, 24.7% Hispanic White, 20.8% non-Hispanic (NH) Asian, 24.7% NH Black, and 38.9% NH White. Plasma eligibility differed across groups in models controlling for covariates (odds ratio from 1.9 to 4.0 compared to the NH White reference group, P < 0.001). Among plasma eligible participants, PET eligibility did not differ by group. DISCUSSION: These results suggest that prevalence of brain amyloid pathology differed, but that eligibility based on plasma was equally effective across racial and ethnic group members. HIGHLIGHTS: Plasma amyloid eligibility is lower in underrepresented racial and ethnic groups. In plasma eligible adults, positron emission tomography eligibility rates are similar across race and ethnicity. Plasma biomarker tests may be similarly effective across racial and ethnic groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.